ATE419871T1 - Verfahren zur behandlung von angststörungen bei älteren personen - Google Patents
Verfahren zur behandlung von angststörungen bei älteren personenInfo
- Publication number
- ATE419871T1 ATE419871T1 AT03719604T AT03719604T ATE419871T1 AT E419871 T1 ATE419871 T1 AT E419871T1 AT 03719604 T AT03719604 T AT 03719604T AT 03719604 T AT03719604 T AT 03719604T AT E419871 T1 ATE419871 T1 AT E419871T1
- Authority
- AT
- Austria
- Prior art keywords
- treating anxiety
- anxiety disorders
- elderly persons
- anxiety
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37546202P | 2002-04-25 | 2002-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE419871T1 true ATE419871T1 (de) | 2009-01-15 |
Family
ID=29270644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03719604T ATE419871T1 (de) | 2002-04-25 | 2003-04-17 | Verfahren zur behandlung von angststörungen bei älteren personen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050129691A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1501531B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005523335A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE419871T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003223474B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2483729A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60325717D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2318123T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003090772A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003279216A1 (en) * | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ES2344645T3 (es) | 2003-02-10 | 2010-09-02 | Applied Molecular Evolution, Inc. | Moleculas de union al abeta. |
| AU2005290250A1 (en) * | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| US20060153772A1 (en) * | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
| PE20061323A1 (es) * | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| NZ568012A (en) * | 2005-12-12 | 2012-07-27 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| RU2498999C2 (ru) * | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008088983A1 (en) | 2007-01-18 | 2008-07-24 | Eli Lilly And Company | PEGYLATED Aβ FAB |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| HRP20150086T1 (xx) * | 2007-06-12 | 2015-02-27 | Ac Immune S.A. | Humanizirana antitijela za beta amiloid |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| PL2238166T3 (pl) * | 2007-10-05 | 2014-07-31 | Genentech Inc | Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu |
| AU2008311366B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| JP5249482B2 (ja) * | 1999-06-16 | 2013-07-31 | ボストン・バイオメデイカル・リサーチ・インステイテユート | インビボのβ−アミロイドレベルの免疫学的制御 |
| EA006606B1 (ru) * | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
| US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
| US7166478B2 (en) * | 2002-03-12 | 2007-01-23 | Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. | Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses |
-
2003
- 2003-04-17 ES ES03719604T patent/ES2318123T3/es not_active Expired - Lifetime
- 2003-04-17 EP EP03719604A patent/EP1501531B1/en not_active Revoked
- 2003-04-17 JP JP2003587405A patent/JP2005523335A/ja not_active Ceased
- 2003-04-17 WO PCT/US2003/010473 patent/WO2003090772A1/en not_active Ceased
- 2003-04-17 AT AT03719604T patent/ATE419871T1/de not_active IP Right Cessation
- 2003-04-17 DE DE60325717T patent/DE60325717D1/de not_active Revoked
- 2003-04-17 AU AU2003223474A patent/AU2003223474B2/en not_active Ceased
- 2003-04-17 US US10/512,527 patent/US20050129691A1/en not_active Abandoned
- 2003-04-17 CA CA002483729A patent/CA2483729A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003090772A1 (en) | 2003-11-06 |
| CA2483729A1 (en) | 2003-11-06 |
| EP1501531A1 (en) | 2005-02-02 |
| AU2003223474B2 (en) | 2008-09-04 |
| US20050129691A1 (en) | 2005-06-16 |
| AU2003223474A1 (en) | 2003-11-10 |
| DE60325717D1 (de) | 2009-02-26 |
| EP1501531A4 (en) | 2006-02-15 |
| EP1501531B1 (en) | 2009-01-07 |
| ES2318123T3 (es) | 2009-05-01 |
| JP2005523335A (ja) | 2005-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60325717D1 (de) | Verfahren zur behandlung von angststörungen bei älteren personen | |
| DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| ATE442592T1 (de) | Detektion und/oder beobachtung von synuclein- assoziierten krankheiten | |
| ATE401395T1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
| EP1701664A4 (en) | SYSTEM AND METHOD FOR PROCESSING A FABRIC | |
| ATE390407T1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
| ATE324908T1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| ATE371454T1 (de) | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie | |
| ATE303379T1 (de) | 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE494296T1 (de) | Zusammensetzungen und verfahren für die tumordiagnose und behandlung | |
| EP1592464A4 (en) | METHOD FOR THE TREATMENT OF COGNITIVE EXPOSURE TO SLEEP LEAVES AND STRESS | |
| DE60224004D1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| DE602005021766D1 (de) | Verfahren zur behandlung von atherosklerose | |
| DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
| ATE287400T1 (de) | 4-(phenylpiperidin-4-ylidenmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| ATE330938T1 (de) | Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen | |
| DE69918541D1 (de) | Verwendung von nmda antagonisten zur behandlung des reizkolons | |
| ATE272619T1 (de) | Anilin-disulfid-derivate zur behandlung allergischer erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |